Cencora, Inc. $COR Shares Sold by FineMark National Bank & Trust

FineMark National Bank & Trust trimmed its stake in Cencora, Inc. (NYSE:COR) by 6.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,540 shares of the company’s stock after selling 557 shares during the quarter. FineMark National Bank & Trust’s holdings in Cencora were worth $2,261,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Private Advisor Group LLC raised its holdings in Cencora by 9.2% during the 1st quarter. Private Advisor Group LLC now owns 6,796 shares of the company’s stock worth $1,890,000 after buying an additional 572 shares during the period. J.W. Cole Advisors Inc. increased its position in shares of Cencora by 49.3% in the first quarter. J.W. Cole Advisors Inc. now owns 6,018 shares of the company’s stock worth $1,674,000 after acquiring an additional 1,987 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Cencora during the first quarter valued at approximately $753,000. Close Asset Management Ltd purchased a new stake in shares of Cencora in the 1st quarter valued at approximately $110,629,000. Finally, Advisors Preferred LLC purchased a new position in Cencora during the 1st quarter worth approximately $725,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently issued reports on COR shares. UBS Group increased their target price on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. Wells Fargo & Company upped their price target on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. TD Cowen raised their price objective on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Robert W. Baird lifted their target price on Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, Evercore ISI set a $400.00 target price on Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $371.09.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. The trade was a 11.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 46,640 shares of company stock worth $14,099,338. 10.80% of the stock is currently owned by company insiders.

Cencora Stock Performance

Shares of COR stock opened at $360.79 on Thursday. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $369.00. The stock’s 50-day moving average is $325.26 and its two-hundred day moving average is $303.65. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The firm has a market cap of $69.95 billion, a P/E ratio of 37.12, a PEG ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the company earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be given a $0.60 dividend. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Cencora’s payout ratio is presently 30.19%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.